Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program
This study evaluates the randomized clinical trials conducted to provide evidence of the safety and effectiveness of cardiovascular devices approved by the Food and Drug Administration (FDA). The FDA approves high-risk devices through premarket approval if it determines the device provides reasonable assurance of safety and effectiveness. The dual goals of this approval process are to ensure patient safety and facilitate access to beneficial technologies. For the past several decades, priority review mandated by legislation has intended to hasten FDA approval, whereby an application receives precedence in review and additional review resources, if needed. The 21st Century Cures Act of 2016 introduced the Breakthrough Devices program, an initiative that is built on but supersedes another program known as Priority Review. Under Breakthrough Devices, the FDA "may accept a greater degree of uncertainty of the benefit-risk profile for these devices if the uncertainty is sufficiently balanced by other factors […] and adequate postmarket controls to support premarket approval."
1 The quality of evidence required for cardiovascular devices to be approved under Priority Review is not known.
Methods | Using publicly available FDA summaries, we conducted a descriptive analysis of pivotal studies that support all high-risk cardiovascular devices approved, from January 1, 2007, to December 31, 2017, through the original premarket process under the Priority Review program. Per the human research policies of the institutional review board of the University of California, San Francisco, this study did not require institutional review board approval, and informed consent was not obtained, as this study involved no human participants. For all studies, we analyzed these design features: number of patients enrolled, randomization, blinding, use and type (active or retrospective) of controls, and post hoc analysis. For all primary end points, we analyzed these characteristics: composite, surrogate, type of analysis (noninferiority, superiority, or objective performance criteria), and achievement of end point. If a device went to an FDA expert device panel, we analyzed the panel's recommendations. We tabulated the postapproval study requirements and the existence of either a Class I ("a reasonable probability that the use … will cause serious adverse health consequences or death") or a Class II ("may cause temporary or medically reversible adverse health consequences or … the probability of serious adverse health consequences is remote") recall. Eighteen pivotal studies were conducted for the 14 cardiovascular devices, and a mean (SD) of 1.3 (0.5) pivotal studies supported each device. None of the 18 studies was double-blind, and 13 studies (72%) used surrogate end points ( Table 1) . The studies enrolled a mean (SD) of 499 (542) patients. Nine studies used a noninferiority hypothesis for at least 1 primary end point. Three device approvals included post hoc analyses, and 2 of these devices did not meet any prespecified primary end points. At the FDA's request, the expert advisory panels reviewed 10 of these devices, including 2 devices that were reviewed for a second time after the requested additional information was provided. There were 9 panel votes on safety and effectiveness, and 4 of 9 votes did not find the devices to be effective ( Table 2 ). The FDA required postapproval clinical studies for 13 of the 14 devices. As of May 23, 2018, there have been 2 Class I and 13 Class II recalls for 6 devices ( Table 2) .
Discussion | We found that most FDA Priority Review approvals for the cardiovascular devices were granted on the basis of a single nonrandomized, nonblinded pivotal study that used surrogate end points, and nearly half of FDA expert advisory panels who reviewed these studies deemed the devices safe but not effective. Our results are consistent with findings in previous studies for cardiovascular devices approved between January 1, 2000, and December 31, 2007, mostly through standard review. 3, 4 Most cardiovascular devices approved under Priority Review are implanted permanently; thus, their risks and benefits should be well understood before clinical use. Highquality preapproval data, studies with a large sample size, and longer follow-up than the mean of 15 months for the studies we reviewed may reduce the likelihood of recalls.
Priority Review places emphasis on confirmatory evidence from postapproval studies. However, previous research has shown that only 13% of postapproval studies were completed 3 to 5 years after FDA approval of a device. 
LESS IS MORE

Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening: A Secondary Analysis of the Danish Lung Cancer Screening Trial
There is uncertainty about the extent of overdiagnosis in lung cancer screening with computed tomography (CT). The National Lung Cancer Screening Trial (NLST) estimated that 18.5% of the cancers detected by CT are overdiagnosed, whereas the Italian Lung Cancer Screening Trial (ITALUNG) found no evidence of overdiagnosis. This study aimed to estimate overdiagnosis of lung cancer by screening CT in the Danish Lung Cancer Screening Trial (DLCST).
Methods | This was an unplanned, post hoc analysis of the DLCST (NCT00496977). [1] [2] [3] In brief, 4104 current or former smokers (≥20 pack-years; former smokers must have quit <10 years before enrollment) aged 50 to 70 years were randomized (1:1) to 5 annual low-dose CT screenings or no screening. The absolute difference in the cumulative incidence of lung cancer in the screened and control groups was assessed 5 years after the last screening round. Overdiagnosis was calculated as the ratio between this difference and the cumulative incidence of screen-detected cancers. The annual lung cancer incidence rate from randomization until the end of follow-up is presented in Figure, A. At the end of follow-up, 96 participants were diagnosed with lung cancer in the screened group (64 cancers were detected by screening) vs 53 participants in the control group. There was a 2.10-percentage point (95% CI, 1.0-3.2 percentage points) increase in the absolute risk of lung cancer with low-dose CT (Figure,  B) . Overdiagnosis was estimated at 67.2% (95% CI, 37.1%-95.4%) of the cancers detected by screening CT.
Discussion | The estimate of overdiagnosis in the DLCST (67.2%) was different from the estimate in the NLST (18.5%; 95% CI, 5.4%-30.6%), 5 and there was no overdiagnosis in the ITALUNG. 6 The contamination of the control group was low: 7.4% until the end of screening and 20.3% at 5-year follow-up. All estimates of overdiagnosis were calculated with similar methods and duration of follow-up. The most extreme estimates were found in the ITALUNG and the DLCST, which shared similar eligibility criteria and study design. 1, 6 Thus, the differences among the trials' results are not adequately explained by differences in participants, interventions, or comparators.
Limitations. The main limitation of the study is the possibility of higher baseline risk of lung cancer in the screened group of 
